Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...
Net Debt: $646 million, a 9% decrease compared to the same period last year. Liquidity Ratio: 2.6 times as of September 30, 2024. Net Leverage Ratio: 1.5 times, in line with the same period last year.
Kazakhstan's biggest oil field Tengiz, operated by U.S. major Chevron, has reduced oil output by 28% to 30% due to ongoing repairs, helping to further tighten global supplies. Repairs were expected to ...
In unwelcome news for mortgage holders, the Reserve Bank’s message is they are not ruling in or out another rate hike, even as much of the developed world moves to lower rates. At its latest meeting ...